Active	Status	Sponsor type	Region	Phase	Filter
13 Active 3 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Prodam, Flavia
NCT06484868: Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy	Recruiting	4	12	Europe	Metreleptin	Amryt Pharma	Partial Lipodystrophy	09/27	09/27
NCT06502990: Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy	Recruiting	3	15	Europe	Metreleptin	Amryt Pharma	Generalized Lipodystrophy	09/26	09/26
NCT04495972: Intestinimonas for Prevention of Type 2 Diabetes Mellitus	Completed	N/A	26	Europe	Intestinimonas-capsules, Placebo-capsules	Caelus Pharmaceuticals BV	PreDiabetes	09/23	11/23
MEASuRE, NCT02325674: Metreleptin Effectiveness And Safety Registry	Recruiting	N/A	100	Europe, US	Metreleptin	Aegerion Pharmaceuticals, Inc.	Generalised Lipodystrophy, Partial Lipodystrophy	10/31	10/31

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Prodam, Flavia
NCT06484868: Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy	Recruiting	4	12	Europe	Metreleptin	Amryt Pharma	Partial Lipodystrophy	09/27	09/27
NCT06502990: Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy	Recruiting	3	15	Europe	Metreleptin	Amryt Pharma	Generalized Lipodystrophy	09/26	09/26
NCT04495972: Intestinimonas for Prevention of Type 2 Diabetes Mellitus	Completed	N/A	26	Europe	Intestinimonas-capsules, Placebo-capsules	Caelus Pharmaceuticals BV	PreDiabetes	09/23	11/23
MEASuRE, NCT02325674: Metreleptin Effectiveness And Safety Registry	Recruiting	N/A	100	Europe, US	Metreleptin	Aegerion Pharmaceuticals, Inc.	Generalised Lipodystrophy, Partial Lipodystrophy	10/31	10/31